FDA flags concerns for AstraZeneca's camizestrant, Truqap ahead of advisory committee meeting

The FDA has released briefing documents detailing its concerns for AstraZeneca’s cancer drugs camizestrant and Truqap ahead of an upcoming advisory committee meeting, the first such gathering in about nine months.

By FiercePharma · May 1, 2026 · via FiercePharma

FDA flags concerns for AstraZeneca's camizestrant, Truqap ahead of advisory committee meeting

Image: FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.